

**Repatha® (evolocumab) 140mg/mL Prefilled Single-Dose Syringe Discontinuation
Healthcare Provider (HCP) FREQUENTLY ASKED QUESTIONS (FAQ)**

Q: How many presentations of Repatha® are there in the US?

- Today there are 2 device presentations of Repatha® in the US:
 - 140 mg/mL prefilled single-dose SureClick® autoinjector
 - 140 mg/mL prefilled single-dose syringe

Q: Why has Amgen decided to discontinue the prefilled syringe? When does that go into effect?

- This decision was made to uphold the high standards that Amgen has set to enable the most optimal patient experience.
- Aligned with this effort, Amgen will discontinue the prefilled syringe by Q1 2026. Patients should transition to the SureClick® autoinjector that is not made with natural rubber latex by the end of 2025.

Q: Is the SureClick® autoinjector not made with natural rubber latex appropriate for all patients?

- The Repatha® SureClick® autoinjector is available and will be appropriate for most patients. However, they will require a new prescription to transition from the prefilled syringe.

Q: Were there safety or quality issues with the prefilled syringe?

- There are no concerns about the drug product quality, efficacy, or patient safety for any of the Repatha® device presentations.
- This decision was made to uphold the high standards that Amgen has set to enable the most optimal patient experience.

Q: How will Amgen support current patients on the prefilled syringe?

- Amgen intends to support the transition of existing patients and help onboard new patients to the SureClick® autoinjector.
- We understand patients will need to transition from their current device.
- Amgen provides patient support and resources, including:
 - Additional SureClick® Demo Kit and samples for healthcare practitioners
 - Patient supplemental injection support by calling the Amgen Nurse Partners® at 1-844-REPATHA (1-844-737-2842) and selecting option 2, Monday – Friday 8:00 am – 8:00 pm.

Q: What should patients do with their existing Repatha® prefilled syringe?

- Patients who are currently in possession of the Repatha® prefilled syringe can continue to take their medicine as directed by their healthcare professional.

Q: Will this action lead to supply shortages?

- Amgen has sufficient product to supply patients during their transition from the prefilled syringe.

Q: Is there a difference in the list prices between the prefilled syringe and SureClick® autoinjector?

- The list price for the SureClick® autoinjector should be the same as the prefilled syringe.

© 2025 Amgen Inc. – All rights reserved.

USA-CCF-83430